PedAM
Pediatric Disease Annotations & Medicines
| Disease | c syndrome |
| Phenotype | C0085580|essential hypertension |
| Sentences | 6 |
| PubMedID- 20662727 | Association of uric acid with risk factors for chronic kidney disease and metabolic syndrome in patients with essential hypertension. |
| PubMedID- 23757400 | Shrs are a model of human essential hypertension with features of metabolic syndrome, including impaired glucose metabolism. |
| PubMedID- 21107432 | The prevalence of metabolic syndrome (mets) in patients with essential hypertension is very high, and has been estimated as being close to 50%.1 hypertensive patients with mets have a much higher cardiovascular (cv) risk than their counterparts without mets,2 and also have a particularly high risk of developing type 2 diabetes mellitus (t2dm).3 in addition, the choice of antihypertensive therapy can have a large impact on the risk of development of t2dm.4 renin–angiotensin system blockers, that is, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (arbs), improve insulin sensitivity and reduce the risk of developing t2dm compared with placebo, whereas calcium channel blockers (ccbs) have a neutral effect. |
| PubMedID- 20016031 | Although recent evidence underscores the role of heme-oxygenase (ho) in diabetes, its effects on insulin sensitivity and glucose metabolism in spontaneously hypertensive rat (shr), a model of essential hypertension with characteristics of metabolic syndrome including insulin resistance/impaired glucose metabolism remains largely unclear. |
| PubMedID- 23096762 | Association of urinary albumin and serum high molecular weight-adiponectin with metabolic syndrome in patients with essential hypertension. |
| PubMedID- 20695936 | Urine albumin excretion, within normal range, reflects increasing prevalence of metabolic syndrome in patients with essential hypertension. |
Page: 1